Citius Oncology, Inc. (CTOR) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-82.3%

$0.11

vs $0.59 price

Levered DCF

$0.00

After debt service

Piotroski score

3 / 9

Weak

Altman Z-score

-2.3

Distress zone

Rating

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022
P/E	-5.97×	-4.63×	-60.16×	-149.8×
P/B	3.32×	2.16×	40.05×	28.41×
P/S	0×	0×	0×	0×
EV / EBITDA	-6.33×	-5.02×	-84.38×	0×
Gross margin	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%
Current ratio	0.56×	0.34×	0.37×	0.46×
Debt / equity	0.08×	0.08×	0×	0×
Interest coverage	-107.89×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022
Return on equity	-55.2%	-45.8%	-49.7%	-30.0%
Return on invested capital	-45.7%	-39.8%	-45.4%	-26.4%
Return on assets	-24.5%	-25.1%	-26.6%	-25.5%
Free cash flow yield	-3.7%	0.1%	-0.1%	-0.0%
Earnings yield	-16.6%	-21.3%	-1.2%	-1.1%
Enterprise value	$148.6M	$103.3M	$1B	$1B
Net debt / EBITDA	0.01×	-0.18×	0×	0×
Cash conversion cycle (days)	0	0	0	0